MDS Symposium | Conference

Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDS

May 7th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Eltrombopag Effectively Treats Cytopenias in MDS

May 2nd 2015

Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.

Somatic Mutations Could Predict Response to Hypomethylating Agents in MDS

May 2nd 2015

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

IPSS Risk and EPO Levels Predict Response to ESAs in MDS

May 2nd 2015

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Dr. Gail Roboz on Molecular Mutations in MDS

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

May 2nd 2015

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

T-Cell Depleted Allografts Lessen GVHD in MDS

May 1st 2015

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.

Lenalidomide Improves Quality of Life in Non-Del5q MDS

May 1st 2015

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

Supportive Care Remains Backbone of Treatment in MDS

May 1st 2015

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS

May 1st 2015

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

Dr. Komrokji on Risk Stratification of Therapy-Related MDS

May 1st 2015

Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.

Novel Agents Sotatercept and Rigosertib Show Potential in MDS

April 30th 2015

OncLive spoke with Guillermo Garcia-Manero, MD, regarding the significance of sotatercept and rigosertib and their potential as therapies in MDS.

HLA-Matched Transplantation Improves OS in High-Risk MDS

April 30th 2015

HLA-matched allogeneic hematopoietic stem cell transplantation was associated with more than a doubling in 4-year overall survival rates for patients with intermediate-2 or high-risk myelodysplastic syndromes.

Dr. Scott on Connect MDS and AML: A Disease Registry

April 30th 2015

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Dr. Garcia-Manero on Rigosertib in Patients with High-Risk MDS After Failure of Hypomethylating Agents

April 30th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.

Sotatercept Effectively Treats Anemia in MDS and Non-Proliferative CMML

April 30th 2015

The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.

Supportive Care Is Key in MDS Treatment

April 28th 2015

Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.